Literature DB >> 6276530

Heterogeneity of biochemical actions among vasodilators.

F C Greenslade, C K Scott, K L Newquist, K M Krider, M Chasin.   

Abstract

Thirty-four vasodilators were screened in several in vitro biochemical assays related to smooth muscle excitation-contraction coupling, binding to beta 1-,beta 2-, and alpha-adrenergic receptors, inhibition of phosphodiesterase activity, and antagonism of calcium accumulation. Isoproterenol and perhexiline only exhibited binding to beta-adrenergic sites. Ergocryptine, tolazoline, and amotriphene only bound to alpha-adrenergic receptors. Leniquinsin, papaverine, proquazone, dioxyline, hoquizil, quazodine, and theophylline were active only as phosphodiesterase inhibitors. Isoxsuprine, nylidrin, and bencyclane bound to alpha- and beta-receptors. Pentoxifylline bound to beta 1-sites and inhibited phosphodiesterase. Cyclandelate bound to beta 2-sites and blocked calcium accumulation. Cinnarizine and flunarizine antagonized calcium accumulation and bound to alpha-sites. Prazosin bound to alpha-sites and inhibited phosphodiesterase. Ethaverine and dipyridamole were inhibitors of phosphodiesterase and calcium accumulation. Nafronyl bound to beta 2- and alpha-sites and antagonized calcium accumulation. Mebeverine bound to beta 2- and alpha-receptors and inhibited phosphodiesterase activity and calcium accumulation. Verapamil bound to alpha-sites, and blocked phosphodiesterase and calcium accumulation. Quinazosin bound to beta 2- and alpha-receptors and antagonized both phosphodiesterase activity and calcium accumulation. Vasodilators that were inactive in all assays included niacin, nicotinyl alcohol, inositol nicotinate, amyl nitrite, sodium nitroprusside, diazoxide, hydralazine, and protoveratrine. Vasodilators should not be considered as a single drug class since they act on various mechanisms related to coupling of neuronal excitation to muscular contractility.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6276530     DOI: 10.1002/jps.2600710123

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds.

Authors:  Gregory J Crowther; Alberto J Napuli; James H Gilligan; Kerstin Gagaring; Rachel Borboa; Carolyn Francek; Zhong Chen; Eleanor F Dagostino; Justin B Stockmyer; Yu Wang; Philip P Rodenbough; Lisa J Castaneda; David J Leibly; Janhavi Bhandari; Michael H Gelb; Achim Brinker; Ingo H Engels; Jennifer Taylor; Arnab K Chatterjee; Pascal Fantauzzi; Richard J Glynne; Wesley C Van Voorhis; Kelli L Kuhen
Journal:  Mol Biochem Parasitol       Date:  2010-09-15       Impact factor: 1.759

2.  Influence of cyclandelate on in vitro red blood cell deformability.

Authors:  D W Hall; W E van den Hoven
Journal:  Drugs       Date:  1987       Impact factor: 9.546

3.  Comparative efficacy of cyclandelate versus flunarizine in the prophylactic treatment of migraine.

Authors:  G Nappi; G Sandrini; G Savoini; A Cavallini; C de Rysky; G Micieli
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  Effect of cyclandelate on prostacyclin release and cytosolic free calcium concentrations in human endothelial cells.

Authors:  V W van Hinsbergh
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  Inhibition of human platelet functions by cyclandelate.

Authors:  W E van den Hoven; D W Hall
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 6.  Role of antispasmodics in the treatment of irritable bowel syndrome.

Authors:  Anita Annaházi; Richárd Róka; András Rosztóczy; Tibor Wittmann
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 7.  Pharmacologic Agents for Chronic Diarrhea.

Authors:  Kwang Jae Lee
Journal:  Intest Res       Date:  2015-10-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.